Markers include VS38c, CD19, CD20, CD27, CD45, CD56, CD81, CD117, CD138, CD269(BCMA), cKappa, and cLambda(12 markers).
The Myeloma MRD Panel by Flow Cytometry evaluates for the presence of minimal residual disease (MRD) in patients with previously diagnosed and treated multiple myeloma. The limit of detection is 0.01%.
- Bone marrow aspirate: 3-4 mL EDTA preferred. Sodium heparin tube is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability.
Ship same day as drawn whenever possible. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.